Stockscreener 앱 받기
22.46
1.36%
-0.31
시장 영업 전:
22.53
0.07
+0.31%
전일 마감가:
$22.77
열려 있는:
$22.77
하루 거래량:
651.62K
Relative Volume:
1.16
시가총액:
$1.09B
수익:
$441.33M
순이익/손실:
$9.76M
주가수익비율:
112.41
EPS:
0.1998
순현금흐름:
$839.00K
1주 성능:
-1.36%
1개월 성능:
-39.35%
6개월 성능:
-50.23%
1년 성능:
-21.08%
1일 변동 폭
$22.17
$23.05
1주일 범위
$21.76
$24.70
52주 변동 폭
$19.16
$48.25
Artivion Inc Stock (AORT) Company Profile
명칭
Artivion Inc
전화
(770) 419-3355
주소
1655 ROBERTS BOULEVARD N W, KENNESAW
Compare AORT vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AORT
Artivion Inc
|
22.46 | 1.11B | 441.33M | 9.76M | 839.00K | 0.1998 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Artivion Inc Stock (AORT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2025-08-13 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2025-06-17 | 개시 | Canaccord Genuity | Buy |
| 2024-10-23 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-27 | 재확인 | Lake Street | Buy |
| 2022-08-08 | 개시 | Lake Street | Buy |
| 2022-03-03 | 개시 | Stifel | Buy |
모두보기
Artivion Inc 주식(AORT)의 최신 뉴스
Artivion Q1 earnings call highlights - MSN
Artivion secures FDA approval for NEXUS aortic arch system - MSN
Artivion (AORT) Q1 earnings and revenues surpass estimates - MSN
Artivion (AORT) director corrects details of restricted stock award - Stock Titan
Artivion (AORT) director receives 7,576-share equity RSA grant - Stock Titan
Artivion Completes Endospan Acquisition, Expands Aortic Arch Portfolio With FDA-Approved NEXUS System - MedTech Intelligence
Artivion (NYSE:AORT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of - Yahoo Finance
Artivion (AORT) director receives 7,850-share stock award, now holds 56,938 - Stock Titan
Artivion Earnings Call Balances Growth With Caution - TipRanks
Artivion closes Endospan buyout to acquire recently approved heart device - MedTech Dive
Artivion Bets On Full Aortic Arch Suite After Endospan Deal - Yahoo Finance
Artivion strengthens aortic arch portfolio with $135m Endospan acquisition - MSN
Artivion (AORT) Completes Acquisition of Endospan for Aortic Sol - GuruFocus
Artivion Closes $175 Million Acquisition of Endospan - Moomoo
Artivion Completes Acquisition of Endospan, Secures FDA Approval for NEXUS Aortic Arch System - Minichart
Artivion secures FDA approval for NEXUS aortic arch device, weighs Endospan acquisition - MSN
Artivion Closes $175M Deal for Aortic Arch Maker Endospan - Medical Product Outsourcing
Artivion completes $175M acquisition of Endospan - Investing.com UK
Artivion completes $175M acquisition of Endospan By Investing.com - Investing.com South Africa
Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System - BioSpace
Artivion Closes Endospan Acquisition Following FDA Approval of NEXUS Aortic System - citybiz
Artivion completes $135 million Endospan acquisition - Investing.com
Artivion completes $135 million Endospan acquisition By Investing.com - Investing.com Australia
Artivion Completes Strategic Acquisition of Endospan Platform - TipRanks
Artivion completes acquisition of Endospan; $131.3M net upfront, up to $200M contingent - TradingView
Endospan acquisition gives Artivion (NYSE: AORT) FDA-approved NEXUS aortic arch system - Stock Titan
Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS - Business Wire
Aortic surgery firm Artivion buys Endospan, NEXUS arch stent maker - Stock Titan
Artivion Completes Acquisition of Endospan Ltd. - PR Newswire
Crafting title options within editorial guidelines An ETF Shop Just Made a Beaten-Down Medtech Its Top Holding - The Motley Fool
Artivion Q1 2026 Earnings: Revenue Matches Estimates, EPS Misses by 35%News and Statistics - IndexBox
5 Insightful Analyst Questions From Artivion’s Q1 Earnings Call - Yahoo Finance
Artivion, Inc. (NYSE:AORT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Artivion shareholders elect directors and approve executive compensation By Investing.com - Investing.com Nigeria
Artivion shareholders elect directors and approve executive compensation - Investing.com
Artivion Shareholders Back Board, Pay and Auditor Choices - TipRanks
Artivion (AORT) shareholders approve directors, executive pay and Ernst & Young for 2026 - Stock Titan
UBS Group AG Has $12.76 Million Position in Artivion, Inc. $AORT - MarketBeat
Artivion Inc (AORT) Shares Surge 3.1% -- What GF Score of 86 Tel - GuruFocus
Artivion Inc (AORT) Shares Surge 3.1% -- What GF Score of 86 Tells Investors - GuruFocus
Artivion (AORT) price target decreased by 16.86% to 43.73 - MSN
Artivion Inc (AORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.22%
1.41%
자본화:
|
볼륨(24시간):